Evoke Pharma, Inc. Study Reports Positive Results Of Metoclopramide Nasal Spray For Gastroparesis In Diabetics
Published: Jan 22, 2014
SAN DIEGO, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.
Help employers find you! Check out all the jobs and post your resume.